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Aim: To compare safety and efficacy of insulin glargine and liraglutide in patients with type 2 diabetes (T2DM).
Methods: This randomized, multinational, open-label trial included subjects treated for T2DM with metformin± sulphonylurea, who had glycated
haemoglobin (HbA1c) levels of 7.5–12%. Subjects were assigned to 24weeks of insulin glargine, titrated to target fasting plasma glucose of 4.0–5.5mmol/L
or liraglutide, escalated to the highest approved clinical dose of 1.8mg daily. The trial was powered to detect superiority of glargine over liraglutide in
percentage of people reaching HbA1c <7%.
Results: The mean [standard deviation (s.d.)] age of the participants was 57 (9) years, the duration of diabetes was 9 (6) years, body mass index was
31.9 (4.2) kg/m2 and HbA1c level was 9.0 (1.1)%. Equal numbers (n= 489) were allocated to glargine and liraglutide. Similar numbers of subjects in both
groups attained an HbA1c level of <7% (48.4 vs. 45.9%); therefore, superiority of glargine over liraglutide was not observed (p= 0.44). Subjects treated
with glargine had greater reductions of HbA1c [−1.94% (0.05) and −1.79% (0.05); p= 0.019] and fasting plasma glucose [6.2 (1.6) and 7.9 (2.2) mmol/L;
p< 0.001] than those receiving liraglutide. The liraglutide group reported a greater number of gastrointestinal treatment-emergent adverse events
(p< 0.001). The mean (s.d.) weight change was +2.0 (4.0) kg for glargine and −3.0 (3.6) kg for liraglutide (p< 0.001). Symptomatic hypoglycaemia was
more common with glargine (p< 0.001). A greater number of subjects in the liraglutide arm withdrew as a result of adverse events (p< 0.001).
Conclusion: Adding either insulin glargine or liraglutide to subjects with poorly controlled T2DM reduces HbA1c substantially, with nearly half of
subjects reaching target levels of 7%.
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Introduction
There is currently no widely accepted paradigm for the
sequence of therapy in type 2 diabetes mellitus (T2DM),
although several sets of guidelines have recently been proposed
[1–3]. Most experts agree that metformin is the drug of first
choice for T2DM, with a variety of oral and injectable therapies
available when glycaemic control is not attained, or is lost,
with this initial approach; however, because injections are
considered by some to be more difficult to initiate than tablets
[4], injectable drugs are usually considered only after two or
more oral agents have been started, and then not until the
glycated haemoglobin (HbA1c) level is substantially elevated
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or patients become symptomatic. The progressive nature of
T2DM [5–8] and inertia in advancing therapy are major
problems contributing to poor glycaemic control for many
patients [9,10].
Although insulin remains the most commonly used
injectable therapy for T2DM, the last decade has brought
drugs based on glucagon-like peptide-1 (GLP-1), a naturally
occurring product of the intestine. Activation of the GLP-1
receptor stimulates insulin secretion, inhibits glucagon release,
delays gastric emptying, reduces hepatic glucose production
and causes satiety [11]. In controlled trials, both basal insulin
and GLP-1 receptor agonists effectively lowered glucose in
patients not reaching glycaemic targets on oral agents [12,13].
These studies were conducted in subjects with good to mod-
erate glycaemic control and HbA1c levels∼8%. The present
Efficacy Assessment of Insulin Glargine vs. Liraglutide after
Oral Agent Failure (EAGLE) trial compared a basal insulin,
insulin glargine, with a GLP-1 receptor agonist, liraglutide, in
a cohort of people with T2DM with poor glycaemic control,
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representative of the population that is frequently started on
injectable drugs. As insulin treatment can be well titrated,
while GLP-1 receptor agonists are delivered at a fixed dose, we
hypothesized that in poorly controlled patients insulin glargine
would be superior to liraglutide.
Methods
Study Design
The EAGLE study was a multicentre, international, 24-week,
comparative, two-arm, parallel, randomized (1 : 1), open-label
trial conducted in 17 countries (Table S1) from August 2010
to October 2012. The comparative study consisted of a 2-week
screening period and a 24-week treatment period with insulin
glargine or liraglutide (Figure 1). Eligible subjects were allo-
cated to liraglutide or insulin glargine randomly through a cen-
tral co-ordinating centre in the order inwhich they qualified for
the study, and stratified by site to ensure a balance in each treat-
ment group (1 : 1 ratio). Neither participants nor investigators
were masked to group assignment. The study was conducted
in accordance with the Declaration of Helsinki and the Guide-
lines on Good Clinical Practice. Every centre obtained local
research ethics committee approval and all participants gave
full informed written consent before entry into the study. The
comparative study was followed by a 24-week extension phase
with a switch to insulin glargine in subjects not adequately
controlled with liraglutide (Figure 1) that ended inMarch 2013.
Subjects
Participants who were aged 35–75 years with a diagnosis of
T2DM for ≥1 year were eligible if they had an HbA1c level
>7.5 and ≤12% (>58 and ≤108mmol/mol), had a body mass
index between 25 and 40 kg/m2 and were willing to comply
with study requirements. To be eligible, subjects were also
required to be on metformin at a minimum dose of 1 g/day,
alone or in combination with sulphonylurea, glinides or a
dipeptidyl peptidase-4 inhibitor for>3months. Those treated
with GLP-1 receptor agonists or insulin in the previous
year, or with thiazolidinediones or 𝛼-glucosidase inhibitors
in the previous 3months were excluded. Other exclusion
criteria included impaired renal (estimated glomerular filtra-
tion rate<60ml/min) or hepatic (alanine aminotransferase/
aspartate aminotransferase >2.5× upper limit of normal)
function, or any condition that investigators felt would com-
promise the patient’s safety or participation in the study.
Subjects receiving liraglutide who had fasting plasma glu-
cose levels ≥13.9mmol/L at weeks 12 or 18 (early switch), or
HbA1c levels ≥7.0% at week 24 of the comparative study were
eligible to be switched to insulin glargine for a 24-week study
extension.
Procedures
Clinic visits were for screening, randomization (week 0) and
follow-up at weeks 2, 6, 12, 18 and 24, with telephone con-
tacts at weeks 1, 3, 4, 8 and 10. All participants received a glu-
cose meter (Accu-Chek Aviva or Performa; Roche Diagnostics
Ltd, Basel, Switzerland) to record self-monitored glucose val-
ues. Individuals randomized to insulin glargine were instructed
on a titration schedule, adjusted every 3 days, to attain fast-
ing plasma glucose levels of ≥4.0 and ≤5.5mmol/l (Table S2).
Self-monitored glucose values and insulin doses were reviewed
electronically by an International Titration Committee dur-
ing the trial and study investigators contacted if titration was
inadequate.
The initial dose of liraglutide was 0.6mg once daily injected
subcutaneously in the morning or evening using a prefilled
pen. The dose was then increased to 1.2 and 1.8mg daily at
weekly intervals if it was well tolerated; doses could be reduced
to 1.2mg in subjects having difficulty with the higher dose. In
both groups, metformin continued at a stable dose, and sulpho-
nylureas were reduced or discontinued at the investigator’s dis-
cretion. Glinides and dipeptidyl peptidase-4 inhibitors were
stopped at randomization.
Participants’ HbA1c levels were recorded at baseline, weeks
12 and 24, while seven-point plasma glucose profiles (before
and 2 h after breakfast, lunch, dinner and at bedtime) were
recorded over three consecutive days before clinic visits at
weeks 0, 12 and 24. Body weight was recorded at weeks 0, 2,
6, 12, 18 and 24. HbA1c and other laboratory blood tests were
analysed at a central laboratory.
The study was powered to show the superiority of insulin
glargine over liraglutide in terms of the percentage of subjects
reaching an HbA1c target of <7% over 24weeks. Secondary
outcomes included change in HbA1c and self-monitored blood
glucose levels. Safety outcomes were treatment-emergent
adverse events (TEAEs) reported by the patient or noted by
the investigator, standard blood chemistry, body weight, vital
signs and hypoglycaemia. Adverse events were not specifically
adjudicated, and discontinuation of the drug was based on
the standard recommendations accompanying drug approval.
Symptomatic hypoglycaemia was defined as an event with typ-
ical symptoms, with or without an associated plasma glucose
level <4.0mmol/L. Severe symptomatic hypoglycaemia was
defined as episodes requiring assistance from another person
associated with a measured plasma glucose level <2.0mmol/L
or, in the absence of a plasma glucose measurement, with
prompt recovery after oral carbohydrate, intravenous glucose
or glucagon administration. Treatment satisfaction and quality
of life were measured using the diabetes treatment satisfaction
questionnaire (DTSQ) and the audit of diabetes-dependent
quality of life (ADDQoL), respectively [14,15]. Eligible sub-
jects in the liraglutide arm (early switch or HbA1c ≥7% at the
end of the comparative phase) consenting to take part in the
extension to the study had clinic visits at weeks 30, 36 and 48
and intervening telephone contacts (Figure 1). Liraglutide was
discontinued, insulin glargine started and the dose titrated in
an identical manner to that used in the comparative trial.
Statistical Analysis
Data analysis was performed using sas version 9.2. All data are
expressed as mean [standard deviation (s.d.)], median (quartile
1 and quartile 3), estimates [standard error (s.e.)] or differences
with 95% confidence interval (CI) as appropriate. Missing
values were imputed using the last observation carried forward
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Figure 1. Study design. HbA1c, glycated haemoglobin; R, randomization; FPG, fasting plasma glucose; OAD(s), oral antidiabetic drug(s).
method. The modified intent-to-treat population included all
participants randomly assigned to treatment groups who had
received at least one dose of the study drug and had at least one
on-treatment assessment of any primary or secondary efficacy
variable, irrespective of compliance with the study protocol
and procedures. All participants randomized and treated were
included in the safety population for analysis.
The superiority of insulin glargine in terms of the percent-
age of participants reaching the HbA1c target of<7% at the
end of the study was tested using a chi-squared test at 5%
level; two-sided 95% CIs of the differences in success rates
(insulin glargine – liraglutide) were also calculated. In the event
that superiority was not demonstrated, there was an a priori
plan to test for non-inferiority of insulin glargine, defined by
a lower limit of the two-sided 95% CI>−3.5% of the rate mea-
sured with liraglutide. Assuming a success rate of 46% with
insulin glargine and 35% with liraglutide and a 10% rate of
non-evaluable participants, a sample of 930 evaluable partici-
pants (465 per arm) was estimated to be necessary to demon-
strate superiority of insulin glargine with a two-sided 𝛼 risk of
5 and 90% power.
For categorical variables, Pearson chi-square or Fisher’s exact
test were used. The rate of hypoglycaemia per patient-year was
analysed using a generalized linear model based on a Poisson,
negative binomial, zero-inflated Poisson or zero-inflated nega-
tive binomial distribution. The best model was fitted according
to the likelihood ratio test and Vuong test.
Results
Disposition of Subjects
Of 1456 participants initially screened, 978 were randomized
to insulin glargine (n= 489) or liraglutide (n= 489; Figure
S1). The completion rate was higher with insulin glargine
(91.4%) than with liraglutide (84.7%). A total of 67 subjects
(13.7%) treated with liraglutide and 37 (7.6%) treated with
insulin glargine withdrew prematurely (p< 0.001), including
34 (7.1%) and 6 (1.2%), respectively, for adverse events
(p< 0.001). The two treatment groups had similar baseline
characteristics (Table 1). Participants had a mean (s.d.) HbA1c
of 9.0 (1.1)% [76 (12)mmol/mol] and a median duration of
diabetes of 8.5 years.
Doses of Insulin Glargine and Liraglutide
At treatment onset the mean (s.d.) daily dose of insulin was
0.15 (0.05)U/kg [13.4 (4.9)U/day], and increased to 0.54
(0.31)U/kg [51.7 (34.1)U/day] at 24weeks. The mean daily
dose of liraglutide at the conclusion of the study was 1.71
(0.24)mg. All subjects continued metformin except for one in
the insulin glargine group. Sulphonylureas were initially taken
by 286 (60%) of those on insulin glargine and by 298 (63%)
receiving liraglutide. At 24weeks, 240 (49%) and 235 (48%),
respectively, were still taking them.
Glycaemic Control
At the end of the comparative study, 226 (48.4%) of 467 par-
ticipants on insulin glargine had HbA1c< 7% compared with
210 (45.9%) of 458 participants on liraglutide. The difference
(insulin glargine–liraglutide) was 2.5% (95% CI −3.9, 8.9%;
p= 0.44); therefore, superiority of insulin glargine was not
observed, nor was non-inferiority of glargine to liraglutide
(p= 0.066).Themean (s.d.) HbA1c level at the end of the com-
parative study was 7.1 (1.0)% [54 (11)mmol/mol] with insulin
glargine and 7.3(1.1)% [56 (12)mmol/mol] with liraglutide
(Figure 2A), with adjustedmean (s.e.) changes of−1.94 (0.05)%
for those on glargine and−1.79 (0.05)% for those on liraglutide.
The adjusted mean difference in HbA1c at the end of the study
was −0.15% (95% CI: −0.28 to −0.02; p= 0.019).The effects of
insulin glargine and liraglutide did not differ across the range of
baselineHbA1c values among the study subjects (Table S3).The
absolute reduction inHbA1cwas progressively greater from the
lowest to the highest quartiles of baseline values, but the relative
effectiveness was comparable with both treatments.
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Table 1. Baseline clinical characteristics of patients included in efficacy analysis (modified intent-to-treat population) – comparative study.
Insulin glargine group, N = 474 Liraglutide group, N = 470
Mean (s.d.) age, years 57.1 (8.8) 57.4 (8.9)
Women, n (%) 224 (47.3) 207 (44.0)
Mean (s.d.) body weight, kg 90.8 (16.6) 90.1 (16.7)
Mean (s.d.) body mass index, kg/m2 32.0 (4.2) 31.8 (4.1)
Median (Q1; Q3) duration of diabetes, years 8.5 (0.9; 34.8) 8.4 (1.0; 33.5)
Mean (s.d.) systolic blood pressure, mmHg 133.2 (15.4) 133.8 (15.5)
Mean (s.d.) diastolic blood pressure, mmHg 80.6 (9.6) 80.5 (8.8)
Mean (s.d.) heart rate, beats/min 74.9 (9.9) 74.6 (9.8)
Median (Q1; Q3) duration of OADs, years 7.2 (0.3; 29.0) 6.8 (0.3; 29.7)
Mean (s.d.) dose of metformin, mg 1939 (557) 1955 (526)
Any late diabetes complication, n (%) 212 (44.7) 223 (47.4)
Macrovascular disease, n (%)
Myocardial infarction 19 (4.0) 19 (4.0)
Angina pectoris 24 (5.1) 26 (5.5)
Coronary artery disease 47 (9.9) 55 (11.7)
Heart failure 4 (0.8) 8 (1.7)
Stroke 9 (1.9) 10 (2.1)
Transient ischaemic attack 4 (0.8) 11 (2.3)
Peripheral vascular disease 34 (7.2) 42 (8.9)
Microvascular disease, n (%)
Diabetic neuropathy 130 (27.4) 143 (30.4)
Diabetic nephropathy 42 (8.9) 46 (9.8)
Diabetic retinopathy 42 (8.9) 40 (8.5)
Any prior antidiabetes medication, n (%) 473 (99.8) 469 (99.8)
Metformin 472 (99.6) 469 (99.8)
Sulphonylurea 320 (67.5) 321 (68.3)
Dipeptidyl peptidase-4 inhibitors 100 (21.1) 100 (21.3)
Glinides 14 (3.0) 16 (3.4)
Alpha-glucosidase inhibitors 1 (0.2) 1 (0.2)
Thiazolidinediones 1 (0.2) 1 (0.2)
Mean (s.d.) HbA1c, % mmol/mol 9.0 (1.0) 9.1 (1.1)
75 (11) 76 (12)
Mean (s.d.) self-monitored fasting plasma glucose, mmol/L 9.8 (2.6) 9.9 (2.6)
Mean (s.d.) total cholesterol, mmol/L 4.6 (1.1) 4.5 (1.1)
Mean (s.d.) LDL cholesterol, mmol/L 2.6 (1.0) 2.6 (0.9)
Mean (s.d.) HDL cholesterol, mmol/L 1.2 (0.3) 1.2 (0.3)
Mean (s.d.) triglycerides, mmol/L 2.3 (1.8) 2.3 (1.6)
Mean (s.d.) aspartate aminotransferase, U/L 23.7 (11.0) 24.0 (11.3)
Mean (s.d.) alanine aminotransferase, U/L 31.5 (15.7) 31.5 (16.7)
Mean (s.d.) serum creatinine, μmol/L 75.9 (16.9) 76.8 (16.5)
Concomitant treatments (other than oral antidiabetic drugs), n (%)
Any 449 (92.8) 453 (93.8)
Antihypertensive agents, n (%)
𝛽-blockers 113 (23.3) 115 (23.9)
Calcium-channel blockers 88 (18.2) 76 (15.8)
Agents acting on renin-angiotensin system 317 (65.5) 315 (65.5)
Lipid-modifying agents 306 (63.2) 294 (61.1)
Antithrombotic agents 191 (39.5) 189 (39.3)
HbA1c, glycated haemoglobin; s.d., standard deviation.
Mean (s.d.) self-monitored fasting glucose was significantly
lower with insulin glargine than with liraglutide at 24weeks
[6.2 (1.6) and 7.9 (2.2)mmol/L; p< 0.001; Figure 2B], as was
mean daily plasma glucose [8.1 (1.6) and 8.6 (2.2)mmol/L;
p< 0.001; Figure 2C).
Safety
Treatment-emergent adverse events were reported by 317
(65.9%) of 481 participants in the liraglutide group and 243
(50.2%) of 484 participants in the insulin glargine group
(p< 0.001; Table 2). More gastrointestinal TEAEs were
reported with liraglutide, including nausea (30.4 vs. 2.7%),
vomiting (9.6 vs.1.7%) and diarrhoea (12.9 vs. 3.7%; all
p< 0.001). Serious TEAEs were reported by 11 (2.3%) subjects
on insulin glargine and 15 (3.1%) on liraglutide, with each type
of event reported by only one individual (Table S4). One case
of acute pancreatitis was reported with liraglutide. Six (1.2%)
of the 484 participants in the insulin glargine group and 34
(7.1%) of the 481 participants in the liraglutide group withdrew
from the study because of a TEAE (Table S5).
Volume 17 No. 2 February 2015 doi:10.1111/dom.12406 173
original article DIABETES, OBESITY AND METABOLISM
Figure 2. (A) Glycated haemoglobin (HbA1c), (B) self-monitored fasting
plasma glucose (SMFPG), (C) mean daily plasma glucose (PG) and (D)
body weight during the comparative study and extension phase. Subjects
treated with liraglutide who had fasting plasma glucose ≥13.9mmol/l at
weeks 12 or 18 (early switch) or had HbA1c ≥7.0% (≥53mmol/mol) at
week 24 of the comparative study were eligible to be switched to insulin
glargine and to be included in the 24-week extension phase. *p= 0.019;
†p< 0.001 compared with liraglutide.
Body weight increased in the insulin glargine group [2.0
(4.0) kg] and decreased in the liraglutide group [3.0 (3.6) kg;
Figure 2D]; the adjusted mean difference was 4.9 kg (95% CI
4.41–5.37; p< 0.001). More participants in the insulin glargine
group (45%) had symptomatic hypoglycaemia than in the
liraglutide group (18%; Table 3). Severe symptomatic hypogly-
caemia did not occur in participants on insulin glargine and
occurred in two participants on liraglutide. No severe noctur-
nal symptomatic hypoglycaemia was reported in either group.
Table 2. Treatment-emergent adverse events (>5% in either group) in the
comparative study safety population.
Insulin glargine
group,
N = 484
Liraglutide
group,
N = 481 p
Any class 243 (50.2) 317 (65.9) <0.001
Gastrointestinal disorders
Nausea 13 (2.7) 146 (30.4) <0.001
Diarrhoea 18 (3.7) 62 (12.9) <0.001
Vomiting 8 (1.7) 46 (9.6) <0.001
Constipation 6 (1.2) 26 (5.4) <0.001
Dyspepsia 4 (0.8) 25 (5.2) <0.001
Infections and infestations
Nasopharyngitis 38 (7.9) 35 (7.3) 0.736
Nervous system disorders
Headache 24 (5.0) 29 (6.0) 0.466
Metabolism and nutrition disorders
Decreased appetite 1 (0.2) 45 (9.4) <0.001
n (%), number and percentage of patients with at least one adverse event.
Systolic blood pressure was reduced (−3.1mmHg) with
liraglutide, while no changes were noted with insulin glargine.
Change in heart rate from baseline was significantly different
between insulin glargine [−0.5 (9.4) bpm] and liraglutide [+2.6
(9.6) bpm]; the adjusted mean difference was −3.1 bpm (95%
CI −4.2, −2.1; p< 0.001; Table S6). Changes in cholesterol and
triglycerides were similar between treatment groups.
Quality-of-life perception improved in both groups and was
similar between the two treatment groups.
Extension Phase
A total of 210 subjects in the liraglutide group were eli-
gible for the extension phase and, of these, 160 (75.2%)
participated (subject characteristics in Table S7). The modified
intent-to-treat population, defined as those treated with ≥1
dose of insulin glargine and with ≥1 assessment of efficacy
after extension entry, comprised 154 subjects; the safety pop-
ulation comprised 160 subjects treated with at least one dose
of glargine in the extension phase. At the start of the extension
phase, all 160 subjects were taking metformin, 89 (56%) were
taking a sulphonylurea and their mean HbA1c level was 8.0
(0.9)% [64 (10)mmol/mol].
The mean (s.d.) dose of insulin increased from 0.18
(0.04)U/kg [15.8 (4.5)U/day] at the start, to 0.55 (0.29)U/kg
[50.9 (27.1)U/day] at the conclusion, of the extension
phase. The mean HbA1c level decreased to 7.7 (0.9)% [61
(10)mmol/mol], giving a mean change of −0.3 (1.1)% [−3
(12)mmol/mol; Figure 2A], with 35 subjects (23%) reaching an
HbA1c level <7%. There were also decreases in self-monitored
fasting blood glucose (Figure 2B) andmean daily blood glucose
(Figure 2C). Body weight increased by 4.4 (3.5) kg over the
course of the extension phase (Figure 2D). The incidence of
symptomatic hypoglycaemia was 35.6%, with nocturnal hypo-
glycaemia in 13.8%, but no reports of severe hypoglycaemia.
Sixty-three subjects (39.4%) experienced a TEAE, with 5
(3.1%) experiencing a serious TEAE and 2 (1.3%) experiencing
a TEAE that led them to discontinue glargine (Table S8).
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Table 3. Rate of symptomatic, severe and nocturnal hypoglycaemia during 24-week treatment with glargine or liraglutide – comparative study (safety
population).
Insulin glargine group
N =484 Liraglutide group N =481
Insulin glargine/liraglutide
for events per patient-year
Patients with
≥1 event*,
n (%)
Estimated
event rate (s.e.)
per patient-year
Patients
with ≥1 event*,
n (%)
Estimated
event rate (s.e.)
per patient-year
Estimated
rate
ratio 95% CI p
All symptomatic
hypoglycaemia
219 (45.2) 7.6 (1.8) 85 (17.7) 1.9 (0.6) 4.0 2.9–5.6 <0.0001
Symptomatic hypoglycaemia
with plasma glucose
≤3.9mmol/L
200 (41.3) 5.1 (0.6) 66 (13.7) 1.1 (0.1) 4.7 3.4–6.6 <0.0001
Nocturnal symptomatic
hypoglycaemia
90 (18.8) 1.4 (0.2) 15 (3.1) 0.1 (0.0) 15.0 8.2–27.5 <0.0001
Nocturnal symptomatic
hypoglycaemia with
plasma
glucose≤ 3.9mmol/L
(70mg/dL)
80 (16.5) 1.3 (0.2) 14 (2.9) 0.1 (0.0) 15.0 8.2–28.5 <0.0001
Severe symptomatic
hypoglycaemia
0 0 2 (0.4) — 0.0 0.0–NE 1.0*
Severe nocturnal
symptomatic
hypoglycaemia
0 0 0 0 — — —
Symptomatic hypoglycaemia
with plasma
glucose≤ 3.1mmol/L
(56mg/dL)
101 (20.9) 1.2 (0.2) 26 (5.4) 0.3 (0.0) 4.7 2.9–7.5 <0.0001
Nocturnal symptomatic
hypoglycaemia with
plasma
glucose≤ 3.1mmol/L
(56mg/dL)
41 (8.5) 0.4 (0.1) 5 (1.0) 0.0 (0.0) 13.4 5.1–34.9 <0.0001
s.e., standard error.
The safety population consisted of all participants randomly assigned to treatment groups and treated. Estimated rate ratios and p values were derived from
a binomial negative model with the exception of that denoted by *, which was from a Poisson model.
Discussion
This trial was designed to compare the effects of two injectable
medications in subjects with T2DM who were not achieving
adequate glycaemic control with oral therapy. In this popu-
lation with poor glycaemic control, both adequately titrated
glargine and liraglutide targeted to the highest approved daily
dose were effective and reducedHbA1c to the predefined target
level of 7% in nearly half the subjects. While glargine caused a
statistically significant greater reduction in HbA1c, the relative
benefit was small (0.15%) and both treatments approached
mean HbA1c reductions of 2% (−1.9% for glargine; −1.8% for
liraglutide). Overall the treatments were well tolerated, with
use of glargine causing more weight gain and hypoglycaemia,
and a higher dropout rate andmore gastrointestinal side effects
with the use of liraglutide. Based on these results, it appears that
addition of once daily injectable therapy is a sound strategy to
improve glycaemic control in patients with high HbA1c levels
on oral therapy.
The subjects in the present study were recruited from mul-
tiple sites around the world, and included overweight and
obese people, most using more than one oral agent, with
mean HbA1c levels of ∼9%. This cohort exemplifies patients
commonly encountered in clinical practice in whom glycaemic
control is so poor that the need to intensify therapy is unam-
biguous, and the starting HbA1c values fit with the level where
many physicians consider starting an injectable medication.
Of the studies currently available that have compared GLP-1
receptor agonists with insulin glargine, the present EAGLE
study cohort had the highest baseline HbA1c [13,16]. Thus,
the study population is a key feature of this trial, representative
as it is of patients with T2DM clearly requiring additional
treatment and making the results readily applicable to clinical
practice.
We predicted that insulin glargine would be the more effec-
tive agent for lowering HbA1c in the present trial because the
dose can be titrated continuously to achieve glycaemic targets.
In fact, titration of glargine in this trial was effective based
on the mean fasting glucose of 6.2mmol/L reached in the
insulin-treated cohort, a level lower than other studies using
similar insulin treatment algorithms [17,18]. Accordingly,
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the decrease in HbA1c level in the present study was greater
than that in other treat-to-target studies, and the percentage
of subjects reaching the HbA1c target of 7% was similar,
despite higher starting baseline values. The effect of liraglutide
with regard to the primary endpoint was also greater in the
present EAGLE study than in previous studies [13,16], and
the effect on HbA1c only slightly smaller than that of glargine.
The relatively large treatment effects in the present study are
probably attributable to the higher starting HbA1c level, as
it is generally acknowledged that the absolute reduction with
treatment is proportional to the starting value [19,20], as
observed in our cohort. The switch from liraglutide to glargine
led to an incremental improvement in HbA1c in the extension
phase, demonstrating additional glucose-lowering efficacy
with insulin over the GLP-1 receptor agonist; however, this
improvement came with increased rates of weight gain and
hypoglycaemia.
Insulin glargine and liraglutide were compared previously
in subjects taking oral agents in the LEAD 5 trial [13]. In that
study subjects with T2DMwith starting HbA1c levels of∼8.2%
received full-dose liraglutide (1.8mg/day), similar to the dose
used in the present study, or titrated glargine. In contrast to
the results of the present EAGLE study, liraglutide reduced
HbA1c slightly, but significantly, more than glargine, and a
greater percentage of subjects reached the target HbA1c of 7%.
However, in Lead 5, the average dose of insulin was∼50% of the
dose used in the present study, and themean fasting glucosewas
7.4mmol/L, ∼20% higher than the glargine-treated subjects in
the present study. It is plausible that with more aggressive use
of insulin, the two treatments in LEAD 5 would have been
comparable as they were in EAGLE.
In addition to fasting glucose level, the mean daily glucose
level based on the subject’s monitoring, was also lower in the
subjects treated with glargine than in those treated with liraglu-
tide. This is compatible with a mechanism of action of basal
insulin to control hepatic glucose production overnight and in
the intermeal intervals [2,21]. Despite significantly higher fast-
ing blood glucose levels in subjects treated with liraglutide, the
changes in HbA1c were comparable, suggesting a greater effect
of the GLP-1 receptor agonist on postprandial glucose. This
effect has also been shown with the GLP-1 receptor agonists
exenatide and lixisenatide, which delay gastric emptying as well
as regulate islet hormone release, responses that are effective in
maintaining glycaemia after eating [11,22,23]. One implication
of these results is that basal insulin andGLP-1 receptor agonists
are complementary and would be effective when used together,
as recently shown in a trial comparing basal insulin plus lixise-
natide with rapid-acting insulin in combination with basal
insulin [24].
In general, participants tolerated their injectable therapies
well over the 24weeks of this trial. While TEAEs were reported
in half the subjects taking glargine and two-thirds of those
on liraglutide, serious adverse events occurred in only 2–3%
of subjects. However, more of the subjects taking liraglutide
(7%) than of those taking glargine (1%) withdrew from the
trial because of treatment effects. In addition, two subjects
taking liraglutide reported severe hypoglycaemia, whereas no
severe hypoglycaemia was reported with glargine. Subjects
taking glargine had a mean increase of body weight of nearly
2 kg, similarly to other studies using a systematic titration
approach [17]. Subjects taking liraglutide lost nearly 3 kg
on average, consistent with a recent meta-analysis of weight
loss with GLP-1 receptor agonists [25]. As expected, glargine
use was associated with greater rates of hypoglycaemia,
occurring at a ∼4-fold greater rate than in the liraglutide
group. Despite use of sulphonylurea in the liraglutide arm by
almost half of the subjects, rates of hypoglycaemia were less
in the present EAGLE trial than in previous trials with this
drug [13].
The present study has some limitations that should be
considered. As glargine and liraglutide have different titration
requirements the study was open-label and thus subject to
investigator/participant bias more than are blinded trials.
Multicentre studies involving insulin titration, even with
prescribed schedules, have more site-to-site variability than
those using fixed-drug dosing. The duration of the study was
relatively short at 6months, although this was in keeping with
similar trials comparing diabetes drugs [13,16,17,26]. The
short study duration may have prevented some subjects in the
glargine group from reaching the target HbA1c. Moreover,
we cannot comment on the durability of treatment responses
and how these might differ between the agents over several
years of treatment. Finally, as only clinical endpoints were
used, any conclusions about the mechanism of action of
glargine and liraglutide in these subjects with diabetes is only
conjectural.
In summary, the EAGLE trial shows that injectable thera-
pies are effective and well tolerated in subjects with poorly con-
trolled T2DM. In this group of subjects with diabetes and poor
glycaemic control, typical of patients in whom diabetes ther-
apy is intensified and injectable therapy frequently considered,
both glargine and liraglutide caused large reductions in HbA1c
levels, such that almost half of the subjects reached a glycaemic
target of 7%. These findings support the use of injectable ther-
apies in subjects with HbA1c values 1.5–2% above goal. The
choice between basal insulin and a GLP-1 receptor agonist will
depend on the potential adverse effects in a given patient as well
as on the cost and availability of medication.
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